CPHI Online Newsletter: Issue 38

The?CPHI Online?Weekly Newsletter brings you the latest bite-size?#pharma?news straight to your LinkedIn inbox.

Want to keep your finger on the pulse?

? Look no further ??subscribe here.

Our spotlight today: Gender Diversity in Pharma

Develop leadership:?Seize challenges, show interest in management roles and inspire others by being an achiever?

From Helena Demuynck, Leadership Coach at oxgyen4leadership to Mindy Leffler, Managing Director of the Qualitative Research and Psychometrics Group at Emmes Endpoint Solutions, our editor Lucy Chard, discusses the importance of gender diversity in healthcare, the workplace and beyond.

Build your network:?Connect with pros inside/outside your area, join events and learn from mentors?

Women are seizing more leadership roles in diverse fields thanks to a growing focus on gender diversity. With increased education and skills, supportive policies, mentoring programs, and networking opportunities, women are gaining valuable exposure to workplace diversity initiatives.?

Champion equality:?Take part in diversity initiatives, share thoughts and experiences to ignite change?

Ms Leffer speaks candidly, honestly and soberly about her child's experiences with Duchenne Muscular Dystrophy and how it became the impetus for starting Emmes Endpoint Solutions research organisation.

Mentor and support:?Serve as an example for others and help talent grow by sharing your knowledge?

Bullet point news:

From oncology, to nutriceutics, 37 novel drugs were approved by the FDA last year. We highlight some of the new drugs to hit the market to date are - including cardiovascular medicine, medicines for conditions of the CNS and those to watch going forward.

• May 2023 -?Inpefa?–?Lexicon Pharmaceuticals?gains?approval for Inpefa, their SGLT1/SGLT2 inhibitor. The drug is approved for used in adults diagnosed with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other conditions leading to a greater risk of cardiovascular disease.?
• May 2023 -?Veozah?– The new treatment for moderate to severe vasomotor symptoms – hot flashes caused by menopause – from?Astellas Pharma?has been approved in a 45 mg once a day dosage.
• March 2023 –?Zavzpret?is a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the treatment of migraine in adults. The nasal spray was tested in a Phase III clinical trial on patients with migraines with or without auras, and compared to a placebo. The spray is the first-of-its-kind treatment from?Pfizer, revolutionising the field.
• February 2023 -?Skycalrys?–?Reata Pharmaceuticals?gained approval for its first drug application in the company’s history, with its oral, daily dosage form for the treatment of Friedreich’s ataxia. The efficacy and safety of Skyclarys was evaluated in a 48-week randomised, placebo-controlled, and double-blind study, Study 1?(NCT02255435)?including 103 patients, and an open-label extension. The FDA granted Orphan Drug, Fast Track, and Rare Paediatric Disease Designations for the medication, and the European Commission also granted Orphan Designation.
• January 2023 -?Brenzazzy?–?TheracosBio?received FDA approval for their oral SGLT2 inhibitor for use as supplementary to exercise and dietary improvements for glycaemic control in patients with type 2 diabetes.

And catch up!

1. Ardena forms partnership with RiboPro to improve mRNA-based therapies
2. Humira biosimilars at discounted prices to meet market demand for accessible treatment

?? ?? ???Aaaaaand that's a wrap!

Thanks all for reading and continue to subscribe to our newsletter for weekly updates of the pharmaceutical industry.